NHD Global
Growth Hormone & IGF · Long-acting GHRH analogue research
Scientific Product Dossier
CJC-1295 with DAC is an albumin-binding, long-acting growth-hormone-releasing-hormone analogue. Two early randomized studies in healthy adults reported sustained GH and IGF-1 increases and an estimated half-life of 5.8–8.1 days. Those values depend on the DAC form and must not be assigned to without-DAC material. FDA reports limited clinical data and serious adverse-event reports.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Mean GH rose 2- to 10-fold for at least 6 days and mean IGF-1 rose 1.5- to 3-fold for 9–11 days; estimated half-life was 5.8–8.1 days.
Healthy adults, short ascending-dose studies, DAC form only.
Read the primary studyFDA identifies limited clinical data, immunogenicity/impurity concerns and serious reports including increased heart rate and systemic vasodilation.
FDA lists CJC-1295 generically in this public summary and does not resolve the marketed DAC/without-DAC form. It is not a finding about a specific catalog lot.
Read the primary studyTwo placebo-controlled studies lasted 28 and 49 days. After a single administration, mean GH increased approximately 2–10-fold for at least 6 days and IGF-I approximately 1.5–3-fold for 9–11 days.
These were pharmacokinetic and endocrine endpoints in adults aged 21–61. They do not establish long-term outcomes, and they must not be assigned to CJC-1295 without DAC.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Teichman SL, et al. Journal of Clinical Endocrinology & Metabolism. 2006. PMID 16352683.
View primary recordFrohman LA, et al. Journal of Clinical Endocrinology & Metabolism. 2006. PMID 17018654.
View primary recordThird-party publications selected for direct relevance.
Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006. PMID 17018654.
Concise answers for researchers comparing identity, evidence and catalog variants.
The drug-affinity-complex group supports albumin binding and prolonged exposure; it is the defining feature behind the published multi-day pharmacokinetics.
No. That estimate belongs to the albumin-binding form studied in the paper.
Family-level identifiers organize the catalog, while the applicable product specification and lot-specific COA control the supplied form, identity and release results.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
The classic CJC-1295 human paper evaluated a long-acting albumin-binding analog in healthy adults. Its sustained hormone profile is evidence for the DAC form studied—not…
Updated August 28, 2026
For CJC-1295 with DAC, the albumin-reactive group is not a branding detail. It changes persistence, analytical behavior and the relevance of the published human…
Updated August 28, 2026Source-traceable evidence
Structured readings of published studies, with the model, result and translation boundary stated explicitly.
A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do…
Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: CD2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
